GHR partner C₂N Diagnostics, a leader in advanced brain health diagnostics, has entered several important partnerships in the last quarter that will advance access to its PrecivityAD blood test. The PrecivityAD test is an innovative new blood test intended for use in patients with cognitive impairment. The test aims to help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease.
Two of these new partnerships expand access to the test in Brazil and Australia. In Brazil, C2N is partnering with Grupo Fleury, one of Brazil’s leading healthcare companies. The partnership will introduce the most advanced set of plasma biomarkers to detect changes that indicate the presence of Alzheimer’s disease pathology in patients experiencing memory difficulties. In Australia, a partnership with Healius Ltd, one of Australia's leading listed healthcare companies, will enable the use of C₂N’s PrecivityAD blood test and related brain health biomarkers in memory and dementia care.
In addition, C2N and Eisai, Inc. are partnering to build awareness about how blood-based assays for cognitive impairment, including Alzheimer’s disease (AD), may help patients receive a timely diagnosis and appropriate treatment, especially in traditionally underserved communities. The development and adoption of blood-based assays in everyday clinical practice is an important step in improving care for people in remote and underserved communities where access to the traditional diagnostic tools of positron emission tomography (PET) and lumbar punctures are not viable options.
C₂N Diagnostics’ Alzheimer's blood test was introduced into the clinic in October of 2020, a breakthrough healthcare innovation for patients, advocates, and physicians who have long awaited an easy to administer test that can help them better understand Alzheimer’s disease.
Learn more about C₂N Diagnostics’ partnerships.
Two of these new partnerships expand access to the test in Brazil and Australia. In Brazil, C2N is partnering with Grupo Fleury, one of Brazil’s leading healthcare companies. The partnership will introduce the most advanced set of plasma biomarkers to detect changes that indicate the presence of Alzheimer’s disease pathology in patients experiencing memory difficulties. In Australia, a partnership with Healius Ltd, one of Australia's leading listed healthcare companies, will enable the use of C₂N’s PrecivityAD blood test and related brain health biomarkers in memory and dementia care.
In addition, C2N and Eisai, Inc. are partnering to build awareness about how blood-based assays for cognitive impairment, including Alzheimer’s disease (AD), may help patients receive a timely diagnosis and appropriate treatment, especially in traditionally underserved communities. The development and adoption of blood-based assays in everyday clinical practice is an important step in improving care for people in remote and underserved communities where access to the traditional diagnostic tools of positron emission tomography (PET) and lumbar punctures are not viable options.
C₂N Diagnostics’ Alzheimer's blood test was introduced into the clinic in October of 2020, a breakthrough healthcare innovation for patients, advocates, and physicians who have long awaited an easy to administer test that can help them better understand Alzheimer’s disease.
Learn more about C₂N Diagnostics’ partnerships.
RSS Feed
